1 results match your criteria: "University of Lille Nord de France and Lille University Hospital[Affiliation]"
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
J Neurol Neurosurg Psychiatry
May 2013
Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France.
Background: Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD).
Methods: We performed a 90-day, randomised, double-blind, study with two parallel arms: 20 mg/day memantine versus placebo (ClinicalTrials.gov:NCT01108029).